Prof. Si Shi 施思
Chief Physician, Professor
Department of Pancreatic Surgery, Fudan University Shanghai Cancer Center, Shanghai
Public profile Compiled from public listings and PubMed. We do not work directly with this doctor, but we can find a specialist in this field to review your case.
Get a specialist opinionClinical focus: Minimally invasive and open surgery for tumors of the pancreas, biliary tract, duodenum, ampulla, retroperitoneum, and spleen. Comprehensive management of complex pancreatic cancer, including personalized combination therapy for second-line or later treatment.
Dr. Shi is a Professor, Chief Physician, and Doctoral Supervisor. Dr. Shi serves as Assistant Director of the Pancreatic Surgery Department at Fudan University Shanghai Cancer Center.
Professional roles
- Vice Chair, Youth Committee of Shanghai Surgical Society
- Member, Youth Committee of Chinese Society of Clinical Oncology (CSCO)
- Member, Tumor Target Molecule Specialty Branch of Shanghai Medical Association
- Standing Committee Member, Youth Council of Shanghai Anti-Cancer Association
Name order: in Chinese the family name comes first (Shi Si). Papers usually list the name as Si Shi or Shi S.
Selected publications
156 papers on PubMed matched by name and affiliation; 71 as first or senior author since 2016. Most recent first- or senior-author papers:
- Cancer Cell, 2026 (first author): Chemotherapy-free phase 1/2 trial of HRS-4642 plus adebrelimab in previously treated metastatic KRAS G12D-mutant pancreatic cancer. PubMed 42748921
- Gut, 2026 (senior author): Integrated screens reveal that guanine nucleotide depletion, which is irreversible via targeting IMPDH2, inhibits pancreatic cancer and potentiates KRAS inhibition. PubMed 41494804
- Gastroenterology, 2026 (senior author): Reply. PubMed 42191044
- Surg Endosc, 2026 (senior author): Multi-label dynamic diagnosis of pancreatic diseases using AI-enhanced endoscopic ultrasound: a multi-cohort real-world study. PubMed 42310197
- Oncogenesis, 2026 (senior author): The emerging role of disulfidptosis in metabolic synergistic death and cancer immunotherapy. PubMed 42230548
- Adv Sci (Weinh), 2026 (senior author): Vorinostat Potentiates Chemoimmunotherapy in Immune-Enriched Pancreatic Cancer. PubMed 41969226
- Gastroenterology, 2026 (senior author): ENPP1-Regulated Extracellular Purine Metabolism Drives Pancreatitis-Mediated Pancreatic Cancer. PubMed 41553309
- Biomark Res, 2026 (senior author): Mitochondrial DNA mutations and intercellular mitochondrial transfer in cancer: mechanisms, biological effects, and clinical potential. PubMed 41639740
See the full PubMed search. Automatic matching can miss papers or include a namesake at the same hospital. This name is shared by other researchers, so we checked that the papers match this doctor's specialty; this check is automatic.
This profile has not been reviewed by the doctor. How we build this directory.
Want a specialist to review your case?
Send your records. We find a specialist in this field who can review your case and write a treatment plan with a cost estimate.
Get a specialist opinion